Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by princeofcuton Jul 21, 2015 10:37am

126 Views

Post# 23944444

RE:RE:RE:RE:RE:July 20, 2015 Filed Via SEDAR

gv, i say yes the AGM is on Sep 30 and it special because i think this year they move from timbits to panera bread as the caterer of choice!!!...i believe Special is now just common boilerplate to enabel them to throw in anything they want in the proxy beyond financials and directors

Bullboard Posts

Gold, growth and sustainability in focus for Mandalay Resources